Cobimetinib is a targeted therapy drug known as a MEK inhibitor. It is designed to interfere with specific molecules involved in the growth, progression, and spread of cancer cells. By inhibiting the MEK enzyme, cobimetinib helps to block the MAPK/ERK signaling pathway, which is often overactive in certain types of cancer.
